Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS
Advertisement
Articles by Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS
Advertisement
Latest Updated Articles
Asciminib May Be an “Attractive” Option in Newly Diagnosed CML PopulationsPublished: June 1st 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC
2
FDA Approves Updated Cosibelimab Label in Cutaneous Squamous Cell Carcinoma
3
ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma
4
Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center
5
